tiprankstipranks
Abbott Laboratories (ABT)
NYSE:ABT
US Market
ABT
Abbott Laboratories
RESEARCH TOOLSreports
Want to see ABT full AI Analyst Report?

Abbott Laboratories (ABT) Stock Forecast & Price Target

9,085 Followers
See the Price Targets and Ratings of:

ABT Analyst Ratings

Strong Buy
21Ratings
Strong Buy
17 Buy
4 Hold
0 Sell
Based on 21 analysts giving stock ratings to
Abbott
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ABT Stock 12 Month Forecast

Average Price Target

$122.78
▲(26.82% Upside)
Based on 21 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $122.78 with a high forecast of $143.00 and a low forecast of $92.00. The average price target represents a 26.82% change from the last price of $96.81.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"91":"$91","144":"$144","104.25":"$104.3","117.5":"$117.5","130.75":"$130.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$143.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":122.77777777777777,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$122.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$92.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[91,104.25,117.5,130.75,144],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,101.741,104.91476923076922,108.08853846153846,111.26230769230769,114.43607692307693,117.60984615384615,120.78361538461539,123.95738461538461,127.13115384615385,130.30492307692307,133.4786923076923,136.65246153846152,139.82623076923076,{"y":143,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,101.741,103.35921367521368,104.97742735042735,106.59564102564103,108.2138547008547,109.83206837606838,111.45028205128204,113.06849572649573,114.6867094017094,116.30492307692307,117.92313675213674,119.54135042735042,121.1595641025641,{"y":122.77777777777777,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,101.741,100.9916923076923,100.24238461538461,99.49307692307693,98.74376923076923,97.99446153846154,97.24515384615384,96.49584615384616,95.74653846153846,94.99723076923077,94.24792307692307,93.49861538461539,92.7493076923077,{"y":92,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":128.458,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.259,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.896,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.532,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.301,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.587,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.385,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.23,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.57,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.881,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.727,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.408,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.741,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$143.00Average Price Target$122.78Lowest Price Target$92.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Daiwa Analyst forecast on ABT
Narumi Nakagiri
Daiwa
Daiwa
$113→$92
Hold
-4.97%
Downside
Downgraded
04/21/26
Abbott downgraded to Neutral from Outperform at DaiwaAbbott downgraded to Neutral from Outperform at Daiwa
Mizuho Securities Analyst forecast on ABT
Anthony Petrone
Mizuho Securities
Mizuho Securities
$125→$115
Hold
18.79%
Upside
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE)
Barclays Analyst forecast on ABT
Matt Miksic
Barclays
Barclays
$144→$143
Buy
47.71%
Upside
Assigned
04/20/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Eli Lilly & Co (NYSE: LLY) and Ionis Pharmaceuticals (NASDAQ: IONS)
UBS Analyst forecast on ABT
Danielle Antalffy
UBS
UBS
$158→$135
Buy
39.45%
Upside
Reiterated
04/20/26
UBS Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Piper Sandler Analyst forecast on ABT
Adam Maeder
Piper Sandler
Piper Sandler
$135→$115
Buy
18.79%
Upside
Reiterated
04/17/26
Piper Sandler Remains a Buy on Abbott Laboratories (ABT)
Oppenheimer Analyst forecast on ABT
Suraj Kalia
Oppenheimer
Oppenheimer
$132→$115
Buy
18.79%
Upside
Reiterated
04/17/26
Abbott price target lowered to $115 from $132 at OppenheimerAbbott price target lowered to $115 from $132 at Oppenheimer
Jefferies Analyst forecast on ABT
Matthew Taylor
Jefferies
Jefferies
$145→$135
Buy
39.45%
Upside
Reiterated
04/17/26
Analysts' Top Healthcare Picks: Rapport Therapeutics, Inc. (RAPP), Abbott Laboratories (ABT)
TD Cowen Analyst forecast on ABT
Josh Jennings
TD Cowen
TD Cowen
$137→$115
Buy
18.79%
Upside
Assigned
04/17/26
Analysts Offer Insights on Healthcare Companies: Equillium (NASDAQ: EQ) and Abbott Laboratories (NYSE: ABT)
Bank of America Securities Analyst forecast on ABT
Travis Steed
Bank of America Securities
Bank of America Securities
$150→$120
Buy
23.95%
Upside
Reiterated
04/17/26
Abbott price target lowered to $120 from $150 at BofAAbbott price target lowered to $120 from $150 at BofA
William Blair Analyst forecast on ABT
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
04/17/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and BioAge Labs, Inc. (NASDAQ: BIOA)
Stifel Nicolaus Analyst forecast on ABT
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
$145→$120
Buy
23.95%
Upside
Assigned
04/17/26
Abbott price target lowered to $120 from $145 at StifelAbbott price target lowered to $120 from $145 at Stifel
Benchmark Co. Analyst forecast on ABT
Bruce Jackson
Benchmark Co.
Benchmark Co.
$145→$120
Buy
23.95%
Upside
Reiterated
04/17/26
Abbott price target lowered to $120 from $145 at BenchmarkAbbott price target lowered to $120 from $145 at Benchmark
BTIG Analyst forecast on ABT
Marie Thibault
BTIG
BTIG
$131
Buy
35.32%
Upside
Reiterated
04/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Decibel Cannabis Company (Other OTC: DBCCF), Abbott Laboratories (NYSE: ABT) and Meiragtx Holdings (NASDAQ: MGTX)
Wolfe Research Analyst forecast on ABT
Michael Polark
Wolfe Research
Wolfe Research
―
Hold
―
Reiterated
04/16/26
Abbott organic outlook cut, says Wolfe ResearchAbbott organic outlook cut, says Wolfe Research
Evercore ISI Analyst forecast on ABT
Vijay Kumar
Evercore ISI
Evercore ISI
$134→$120
Buy
23.95%
Upside
Reiterated
04/16/26
Abbott price target lowered to $120 from $134 at Evercore ISIAbbott price target lowered to $120 from $134 at Evercore ISI
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Daiwa Analyst forecast on ABT
Narumi Nakagiri
Daiwa
Daiwa
$113→$92
Hold
-4.97%
Downside
Downgraded
04/21/26
Abbott downgraded to Neutral from Outperform at DaiwaAbbott downgraded to Neutral from Outperform at Daiwa
Mizuho Securities Analyst forecast on ABT
Anthony Petrone
Mizuho Securities
Mizuho Securities
$125→$115
Hold
18.79%
Upside
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE)
Barclays Analyst forecast on ABT
Matt Miksic
Barclays
Barclays
$144→$143
Buy
47.71%
Upside
Assigned
04/20/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Eli Lilly & Co (NYSE: LLY) and Ionis Pharmaceuticals (NASDAQ: IONS)
UBS Analyst forecast on ABT
Danielle Antalffy
UBS
UBS
$158→$135
Buy
39.45%
Upside
Reiterated
04/20/26
UBS Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Piper Sandler Analyst forecast on ABT
Adam Maeder
Piper Sandler
Piper Sandler
$135→$115
Buy
18.79%
Upside
Reiterated
04/17/26
Piper Sandler Remains a Buy on Abbott Laboratories (ABT)
Oppenheimer Analyst forecast on ABT
Suraj Kalia
Oppenheimer
Oppenheimer
$132→$115
Buy
18.79%
Upside
Reiterated
04/17/26
Abbott price target lowered to $115 from $132 at OppenheimerAbbott price target lowered to $115 from $132 at Oppenheimer
Jefferies Analyst forecast on ABT
Matthew Taylor
Jefferies
Jefferies
$145→$135
Buy
39.45%
Upside
Reiterated
04/17/26
Analysts' Top Healthcare Picks: Rapport Therapeutics, Inc. (RAPP), Abbott Laboratories (ABT)
TD Cowen Analyst forecast on ABT
Josh Jennings
TD Cowen
TD Cowen
$137→$115
Buy
18.79%
Upside
Assigned
04/17/26
Analysts Offer Insights on Healthcare Companies: Equillium (NASDAQ: EQ) and Abbott Laboratories (NYSE: ABT)
Bank of America Securities Analyst forecast on ABT
Travis Steed
Bank of America Securities
Bank of America Securities
$150→$120
Buy
23.95%
Upside
Reiterated
04/17/26
Abbott price target lowered to $120 from $150 at BofAAbbott price target lowered to $120 from $150 at BofA
William Blair Analyst forecast on ABT
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
04/17/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and BioAge Labs, Inc. (NASDAQ: BIOA)
Stifel Nicolaus Analyst forecast on ABT
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
$145→$120
Buy
23.95%
Upside
Assigned
04/17/26
Abbott price target lowered to $120 from $145 at StifelAbbott price target lowered to $120 from $145 at Stifel
Benchmark Co. Analyst forecast on ABT
Bruce Jackson
Benchmark Co.
Benchmark Co.
$145→$120
Buy
23.95%
Upside
Reiterated
04/17/26
Abbott price target lowered to $120 from $145 at BenchmarkAbbott price target lowered to $120 from $145 at Benchmark
BTIG Analyst forecast on ABT
Marie Thibault
BTIG
BTIG
$131
Buy
35.32%
Upside
Reiterated
04/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Decibel Cannabis Company (Other OTC: DBCCF), Abbott Laboratories (NYSE: ABT) and Meiragtx Holdings (NASDAQ: MGTX)
Wolfe Research Analyst forecast on ABT
Michael Polark
Wolfe Research
Wolfe Research
―
Hold
―
Reiterated
04/16/26
Abbott organic outlook cut, says Wolfe ResearchAbbott organic outlook cut, says Wolfe Research
Evercore ISI Analyst forecast on ABT
Vijay Kumar
Evercore ISI
Evercore ISI
$134→$120
Buy
23.95%
Upside
Reiterated
04/16/26
Abbott price target lowered to $120 from $134 at Evercore ISIAbbott price target lowered to $120 from $134 at Evercore ISI
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

3 Months
xxx
Success Rate
32/44 ratings generated profit
73%
Average Return
+4.72%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +4.72% per trade.
1 Year
Jayson BedfordRaymond James
Success Rate
35/44 ratings generated profit
80%
Average Return
+16.67%
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 79.55% of your transactions generating a profit, with an average return of +16.67% per trade.
2 Years
xxx
Success Rate
14/21 ratings generated profit
67%
Average Return
+28.09%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +28.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABT Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
1
1
1
0
Buy
38
36
31
32
36
Hold
2
1
1
2
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
40
38
33
35
42
In the current month, ABT has received 36 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. ABT average Analyst price target in the past 3 months is 122.78.
Each month's total comprises the sum of three months' worth of ratings.

ABT Financial Forecast

ABT Earnings Forecast

Next quarter’s earnings estimate for ABT is $1.28 with a range of $1.26 to $1.32. The previous quarter’s EPS was $1.15. ABT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.
Next quarter’s earnings estimate for ABT is $1.28 with a range of $1.26 to $1.32. The previous quarter’s EPS was $1.15. ABT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Sales Forecast

Next quarter’s sales forecast for ABT is $12.54B with a range of $12.35B to $12.70B. The previous quarter’s sales results were $11.16B. ABT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.
Next quarter’s sales forecast for ABT is $12.54B with a range of $12.35B to $12.70B. The previous quarter’s sales results were $11.16B. ABT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Stock Forecast FAQ

What is ABT’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 122.78.
    What is ABT’s upside potential, based on the analysts’ average price target?
    Abbott Laboratories has 26.82% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ABT a Buy, Sell or Hold?
          Abbott Laboratories has a consensus rating of Strong Buy which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Abbott Laboratories’s price target?
            The average price target for Abbott Laboratories is 122.78. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $143.00 ,the lowest forecast is $92.00. The average price target represents 26.82% Increase from the current price of $96.81.
              What do analysts say about Abbott Laboratories?
              Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
                How can I buy shares of ABT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.